1765192
Last Update Posted: 2017-02-01
Recruiting has ended
All Genders accepted | 18 Years + |
64 Estimated Participants | No Expanded Access |
Interventional Study | Does not accept healthy volunteers |
Roflumilast Plus Montelukast in Adults With Severe Asthma
This study will evaluate the effect of roflumilast 500 μg once daily (QD) plus montelukast 10 mg QD versus 10 mg montelukast QD alone on predose (trough) prebronchodilator forced expiratory volume in the first second (FEV1).
The drug being tested in this study is called roflumilast. Roflumilast is being tested to treat people who have asthma. This study will look at lung function and asthma symptoms of people who take roflumilast in combination with montelukast.
Eligibility
Relevant conditions:
Asthma
If you aren't sure if you meet the criteria above speak to your healthcare professional. Criteria may be updated but not reflected here, do not hesitate to contact the trial if you think are close to fitting criteria.
locations
Data sourced from ClinicalTrials.gov